Navigation Links
Dyadic International Reports 2011 First Quarter Financial Results
Date:5/5/2011

JUPITER, Fla., May 5, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the quarter ended March 31, 2011. The financial information contained in this press release should be read in conjunction with the financial statements and related footnotes which have been posted on the OTC Markets website at www.otcmarkets.com and on Dyadic's website at www.dyadic.com.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "During the first quarter, Dyadic achieved strong growth in research revenue which continues to serve as the proving ground for future licensing and other third party collaborations. We also experienced improving margins in our enzyme business and launched two new products for the pulp & paper and biofuels markets which are currently being sampled and undergoing trials by new and existing customers. Finally, we added to the value and protection of our products and technologies with the issuance of several new U.S. patents."

First Quarter Highlights and Recent Events

  • Total revenue for the first quarter increased approximately 15% over the same period last year highlighted by a greater than five-fold increase in research and development revenue
  • Product margins for the first quarter increased compared to the previous year's first quarter
  • Gross profit for the first quarter increased by approximately 95% over the same period last year as a result of higher research revenue, improved product margins and further cost controls and operational efficiencies
  • Launched two new products: FibreZyme® G200 and AlternaFuel® CMAX™, for the pulp and paper and biofuels markets
  • Received four new U.S. patents
  • Completed negotiations and entered into R&D collaboration with Sanofi Pasteur and EnGen Bio for certain vaccine applications of Dyadic's patented C1 technology

  • Financial ResultsTotal revenue for the three months ended March 31, 2011 increased approximately 15% to approximately $2.3 million, as compared to approximately $2.0 million for the three months ended March 31, 2010.  The increase was primarily attributable to research revenue of approximately $491,000 for the three months ended March 31, 2011, as compared to approximately $88,000 for the same period in the prior year, reflecting Dyadic's continued commitment to increasing its revenue-generating research and development projects in addition to internally funded projects.

    Gross profit for the first quarter of 2011 increased approximately 95% to approximately $768,000 from approximately $394,000 in the first quarter of 2010. The increase was due mainly to higher gross margins on product sales, increased research and development activity which generally has higher contribution margins, and further cost controls and operational efficiencies.

    General and administrative expenses for the three months ended March 31, 2011 increased approximately 24% to approximately $1.7 million, as compared to approximately $1.4 million for the same period last year due primarily to increased litigation costs.

    Net loss for the quarter ended March 31, 2011 was approximately $1.5 million, or $(0.05) per basic and diluted share, as compared to a net loss of approximately $1.1 million, or $(0.04) per basic and diluted share for the quarter ended March 31, 2010. In 2010, Dyadic recorded a gain on reduction of accrued stockholder litigation of $410,000, which accounted for the majority of the difference.

    At March 31, 2011, cash and cash equivalents were approximately $3.1 million and working capital was approximately $4.2 million.

    About DyadicDyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.

    Dyadic makes financial disclosures through the OTC Disclosure and News Service which offers free information on the OTC Markets website (www.otcmarkets.com) concerning companies traded on the OTC Markets. Investors can access and download Dyadic's financial reports and other announcements that Dyadic makes through the OTC Markets website. Dyadic will also continue providing updates through regular press releases as appropriate.

    Cautionary Statement for Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree Months Ended March 31,20112010Revenue: (Unaudited) (Unaudited) Product Related Revenue, Net

    $

    1,805,208

    $

    1,879,145License Fee Revenue-32,000Research and Development Revenue491,30988,235Total Revenue2,296,5171,999,380Cost of Goods Sold1,528,2271,605,324Gross Profit768,290394,055Expenses:General and Administrative1,684,6901,359,667Sales and Marketing 267,734226,733Research and Development 304,003286,042Foreign Currency Exchange Losses (Gains), Net(94,034)33,294Total Expenses2,162,3931,905,736(Loss) from Operations(1,394,103)(1,511,681)Other Income (Expense):Interest Income4,19121,270Interest Expense(113,006)(33,379)Gain on Reduction of Accrued Stockholder Litigation-410,000Total Other Income (Expense)(108,815)397,891Net (Loss)

    $

    (1,502,918)

    $

    (1,113,789)Net (Loss) per Common ShareBasic

    $

    (0.05)

    $

    (0.04)Diluted

    $

    (0.05)

    $

    (0.04)Weighted Average Common Shares Used in Calculating Net (Loss) Per Share:Basic31,150,62030,832,621Diluted31,150,62030,832,621DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSMarch 31, 2011December 31, 2010ASSETS(Unaudited)Current Assets:Cash and Cash Equivalents$

    3,121,189$

    4,535,279Restricted Cash263,934247,082Accounts Receivable, Net1,517,1571,276,574Inventory, Net2,831,1892,782,433Prepaid Expenses and Other Current Assets447,490336,638Total Current Assets8,180,9599,178,006Fixed Assets, Net648,631719,161Intangible Assets, Net354,609310,978Other Assets16,92916,930$

    9,201,128$

    10,225,075LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts Payable$

    1,925,827$

    1,801,123Accrued Expenses511,010417,996Accrued Interest Payable  112,283146,230Note Payable to Stockholder1,424,9411,424,941Income Taxes Payable168168Total Current Liabilities3,974,2293,790,458Convertible Subordinated Debt4,000,0004,000,0007,974,2297,790,458COMMITMENTS AND CONTINGENCIESStockholders’ Equity:Preferred Stock, $.0001 Par Value:Authorized Shares – 5,000,000; None Issued and Outstanding--Common stock, $.001 par value,Authorized Shares – 100,000,000; Issued and Outstanding  – 31,163,120 and 31,138,120, Respectively31,16331,138Additional Paid-in Capital77,396,86577,101,690Accumulated Deficit(76,201,129)(74,698,211)1,226,8992,434,617$

    9,201,128$

    10,225,075DYADIC INTERNATIONALCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Three Months Ended March 31, 2011 2010 (Unaudited) (Unaudited) Operating ActivitiesNet (Loss)

    $

    (1,502,918)$

    (1,113,790)Adjustments to Reconcile Net (Loss) to Net Cash (Used in) Operating Activities:Depreciation and Amortization of Fixed Assets70,53271,712Amortization of Intangible and Other Assets7,4903,515Provision for Doubtful Accounts11,839-Recovery of Inventory Reserve(75,389)(97,713)Compensation Expense on Stock Option Grants291,450196,102Stock Issued for Financial Services-63,000Gain on Reduction of Accrued Stockholder Litigation-(410,000)Changes in Operating Assets and Liabilities:Accounts Receivable(252,422)5,049Inventory26,633450,985Prepaid Expenses and Other Current Assets(110,852)34,504Other Assets-(12,588)Accounts Payable124,70447,084Accrued Expenses93,014(101,563)Accrued Interest Payable(33,947)(26,459)Deferred Research and Development Obligation-90,614Income Taxes Payable-(767)Net Cash (Used In) Operating Activities(1,349,866)(800,315)Investing ActivitiesPurchases of Fixed Assets-(104,622)Cost of Patents(51,122)-Restricted Cash(16,852)(1,429)Net Cash (Used In) Investing Activities(67,974)(106,051)Financing ActivitiesProceeds from Stock Option Exercises3,75015,093Proceeds from Stock Warrant Exercises-16,876Net Cash Provided by Financing Activities3,75031,969Net (Decrease) in Cash and Cash Equivalents(1,414,090)(874,397)Cash and Cash Equivalents at Beginning of Period4,535,2798,419,934Cash and Cash Equivalents at End of Period

    $

    3,121,189$

    7,545,537Supplemental Cash Flow Information:Cash Paid for Interest

    $

    146,953$

    59,838
    '/>"/>

    SOURCE Dyadic International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Two New U.S. Patents Issued to Dyadic International
    2. Dyadic International to Announce 2010 Year-End Financial Results and Hold Conference Call on March 10, 2011
    3. Sixth U.S. Patent Issued to Dyadic International
    4. Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference
    5. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
    6. Dyadic International Reports 2010 Second Quarter Financial Results
    7. Bacterin International Holdings Launches Third Biologic Scaffold
    8. INC Research to Acquire Kendle International for $15.25 per Share in Cash
    9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Growth Stock Conference
    10. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
    11. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... , Feb. 11, 2016 Potrero Medical, Inc., ... pleased to announce the appointment of George M. Rapier, ... San Antonio, TX , WellMed is one of ... 200,000 patients and HMO members in Texas ... in 1990 out of his own internal medicine practice, he ...
    (Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
    (Date:2/11/2016)... , Feb. 11, 2016  MiMedx Group, Inc. ... utilizing human amniotic membrane and other birth tissues, human ... to develop and market advanced products and therapies, announced ... Markets, 2016 Global Healthcare Conference in New ... and CEO, Michael J. Senken , Chief Financial ...
    Breaking Medicine Technology:
    (Date:2/11/2016)... ... , ... The president released a FY 2017 budget request on Tuesday that ... the cost burden to military beneficiaries. , MOAA’s president, retired Air Force Lt. ... including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We were ...
    (Date:2/11/2016)... ... 2016 , ... The Chartis Group, a national advisory services ... the “2015/2016 Best in KLAS: Software and Services” report in two categories: IT ... insights firm on a global mission to improve healthcare delivery by amplifying the ...
    (Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... to reverse diabetes has been gearing up for their simultaneous grand openings in ... It’s about right now that you’re probably wondering, is reversing diabetes possible? According ...
    (Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... advocates will discuss how to improve care by making data on heart procedures ... disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart ...
    (Date:2/11/2016)... ... February 11, 2016 , ... Thermi™, a world leader ... to announce the promotions of Allison Kelly to executive vice president of the ... vice president of North American capital sales, and Wendy Oseas to vice president ...
    Breaking Medicine News(10 mins):